Post-transplant hypophosphatemia: Tertiary 'Hyper-Phosphatoninism'? (scientific article published on 30 August 2006)

The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency

Q28202356

Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23

Q28209679

Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production

Q28213962

Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)

Q28236767

Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo

Q28572995

Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers

Q33974129

FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting

Q34227442

Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease

Q34557934

Novel aspects in regulated expression of the renal type IIa Na/Pi-cotransporter

Q35907144

Nomogram for derivation of renal threshold phosphate concentration

Q39338652

Fibroblast growth factor 7: an inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors

Q40488393

Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders

Q40530218

Evidence for a PTH-independent humoral mechanism in post-transplant hypophosphatemia and phosphaturia.

Q40782837

Prolongation of allograft survival by 1,25-dihydroxyvitamin D3.

Q42538603

Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia

Q44203982

Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia

Q44414604

Tacrolimus decreases tubular phosphate wasting in renal allograft recipients

Q44608622

Influence of 1,25-dihydroxyvitamin D3 as an immunomodulator in renal transplant recipients: a retrospective cohort study

Q44707794

Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis

Q44779387

Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis

Q44835152

FGF-23 in patients with end-stage renal disease on hemodialysis

Q44846350

Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency.

Q44985964

Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men.

Q45197408

Vitamin D and phosphate regulate fibroblast growth factor-23 in K-562 cells

Q45238632

Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis.

Q45964561

Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy

Q46410798

The role of fibroblast growth factor 23 for hypophosphatemia and abnormal regulation of vitamin D metabolism in patients with McCune-Albright syndrome

Q46444314

Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States

Q46547776

Fibroblast growth factor 23 is increased in calcium nephrolithiasis with hypophosphatemia and renal phosphate leak.

Q46849862

Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD.

Q46907551

FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa.

Q54733425

Effect of daily oral vitamin D and calcium therapy, hypophosphatemia, and endogenous 1-25 dihydroxycholecalciferol on parathyroid hormone and phosphate wasting in renal transplant recipients

Q57226018

Decreased phosphate reabsorption after renal transplantation: Evidence for a mechanism independent of calcium and parathyroid hormone

Q72895780

Metabolic aspects of phosphate replacement therapy for hypophosphatemia after renal transplantation: impact on muscular phosphate content, mineral metabolism, and acid/base homeostasis

Q73181296

Post-transplant hypophosphatemia

Q73942952

Incidence of vertebral fractures in the first three months after orthotopic liver transplantation

Q74221573

PTH 1-84 and PTH "7-84" in the noninvasive diagnosis of renal bone disease

Q74537055

Prospective study of calcium homeostasis after renal transplantation

Q74580312

Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women

Q79995263

P433

issue

P407

language of work or name

English

Q1860

P304

page(s)

1486-1494

P577

publication date

2006-08-30

P1433

published in

Kidney International

Q6404823

P1476

title

Post-transplant hypophosphatemia: Tertiary 'Hyper-Phosphatoninism'?

P478

volume

Reverse relations

cites work (P2860)

Q36381365	A Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation
Q42142847	A Randomized Study Comparing Parathyroidectomy with Cinacalcet for Treating Hypercalcemia in Kidney Allograft Recipients with Hyperparathyroidism
Q37552700	A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease
Q35869678	Approach to the hypophosphatemic patient
Q50474692	Beneficial effects of preemptive kidney transplantation on calcium and phosphorus disorders in early post-transplant recipients.
Q40091099	Bone Disease and Serum Fibroblast Growth Factor-23 Levels in Renal Transplant Recipients
Q84912100	Bone disease after renal transplantation
Q35463999	CKD-MBD after kidney transplantation
Q89029596	Calcitriol Reduces Albuminuria and Urinary Angiotensinogen Level in Renal Transplant Recipients
Q100440285	Changes in Fibroblast Growth Factor 23 and Soluble Klotho Levels After Hemodialysis Initiation
Q87653257	Changes in bone mineral metabolism parameters, including FGF23, after discontinuing cinacalcet at kidney transplantation
Q83828745	Clinical manifestations of hypercalcemia and hypophosphatemia after kidney transplantation
Q37824821	Clinical practice. Fibroblast growth factor (FGF)23: a new hormone
Q37641052	Clinical relevance of FGF-23 in chronic kidney disease
Q45978599	Determination of optimal cholecalciferol treatment in renal transplant recipients using a population pharmacokinetic approach.
Q37912038	Diseases of the parathyroid gland in chronic kidney disease.
Q37507342	Disorders of phosphate homeostasis and tissue mineralisation
Q46314704	Effects of vitamin D supplementation on the calcium-phosphate balance in renal transplant patients
Q30427104	Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality
Q83828751	Elevated fibroblast growth factor 23 levels as a cause of early post-renal transplantation hypophosphatemia
Q42151684	FGF-23 Levels before and after Renal Transplantation
Q35156017	FGF-23: More than a regulator of renal phosphate handling?
Q37228152	FGF23 and mineral metabolism in the early post-renal transplantation period
Q37584801	FGF23 and syndromes of abnormal renal phosphate handling
Q37284113	FGF23 is associated with early post-transplant hypophosphataemia and normalizes faster than iPTH in living donor renal transplant recipients: a longitudinal follow-up study.
Q37654689	FGF23-parathyroid interaction: implications in chronic kidney disease
Q42234272	Fibroblast Growth Factor and Mineral Metabolism Parameters among Prevalent Kidney Transplant Patients
Q28075648	Fibroblast Growth Factor-23-A Potential Uremic Toxin
Q36756061	Fibroblast growth factor 23 and bone mineralisation
Q34281434	Fibroblast growth factor-23 and parathyroid hormone are associated with post-transplant bone mineral density loss
Q43037617	Immunosuppressive agents and bone disease in renal transplant patients with hypercalcemia.
Q84342673	Impaired regulation of calcium excretion in kidney transplant recipients
Q33591785	Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation
Q37384718	Latest findings in phosphate homeostasis
Q30418461	Management of mineral and bone disorder after kidney transplantation
Q26771398	Mineral and bone disorder after kidney transplantation
Q37034289	Mineral and bone disorder after renal transplantation: a review
Q37938689	Mineral and bone disorders in children with chronic kidney disease
Q38452732	Mineral and bone disorders in kidney transplant recipients: reversible, irreversible, and de novo abnormalities
Q39823001	Parathyroid resistance to FGF23 in kidney transplant recipients: back to the past or ahead to the future?
Q49449891	Paricalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients.
Q81343793	Persistent high level of fibroblast growth factor 23 as a cause of post-renal transplant hypophosphatemia
Q35025469	Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease
Q37551655	Post-renal transplantation hypophosphatemia
Q36947345	Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation
Q36739668	Regulation of phosphate homeostasis by the phosphatonins and other novel mediators
Q35758546	Renal phosphate loss in long-term kidney transplantation
Q59419742	Sclerostin and Dickkopf-1 in Post-menopausal Renal Allograft Recipients
Q31078603	Sirolimus induced phosphaturia is not caused by inhibition of renal apical sodium phosphate cotransporters
Q34500628	Tertiary excess of fibroblast growth factor 23 and hypophosphatemia following kidney transplantation
Q24625902	The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis
Q38584122	The Kidney-Vascular-Bone Axis in the Chronic Kidney Disease-Mineral Bone Disorder
Q38020094	The role of FGF23 in CKD--with or without Klotho.
Q37715190	Treatment with calcimimetics in kidney transplantation
Q55117716	Tumor-Induced Osteomalacia.
Q36210285	Update on fibroblast growth factor 23 in chronic kidney disease
Q55496554	Uremic Toxins and Clinical Outcomes: The Impact of Kidney Transplantation.
Q34517376	VITamin D supplementation in renAL transplant recipients (VITALE): a prospective, multicentre, double-blind, randomized trial of vitamin D estimating the benefit and safety of vitamin D3 treatment at a dose of 100,000 UI compared with a dose of 12,0
Q34069825	Vitamin D in organ transplantation
Q34497264	Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials